Original ArticleNo Access

Collagenase and the Treatment of Dupuytren Contracture: Efficacy of Treatment and Patient Satisfaction

Department of Trauma & Orthopaedic Surgery, University Hospital Galway, Merlin Park, Galway, Ireland

Correspondence to: Kevin Clesham, Specialist Registrar in Trauma & Orthopaedic Surgery, Department of Trauma & Orthopaedic Surgery, University Hospital Galway, Merlin Park, Galway, Ireland. Tel: +353861296081,

Search for more papers by this author

Gerard A. SHERIDAN

Department of Trauma & Orthopaedic Surgery, University Hospital Galway, Merlin Park, Galway, Ireland

Search for more papers by this author

Evelyn P. MURPHY

Department of Trauma & Orthopaedic Surgery, University Hospital Galway, Merlin Park, Galway, Ireland

Search for more papers by this author

Sharon P. O’ CONNOR

Department of Orthopaedic Physiotherapy, University Hospital Galway, Merlin Park, Galway, Ireland

Search for more papers by this author

, and

Michael E. O’ SULLIVAN

Department of Trauma & Orthopaedic Surgery, University Hospital Galway, Merlin Park, Galway, Ireland

Search for more papers by this author

https://doi.org/10.1142/S2424835522500138Cited by:3 (Source: Crossref)

Abstract

Background: Collagenase clostridium histolyticum has become a widely used treatment in the management of Dupuytren disease. The aims of this study are to assess the immediate success of treatment of Dupuytren contracture with collagenase injection, to measure long-term patient-rated outcomes, to determine whether the risk factors for the disease impacted outcomes and to report complications of collagenase treatment.

Methods: A prospective study was performed in a tertiary referral centre. Measurements were recorded pre-treatment, day 1 and day 90. Patient-rated outcome scores were measured using Disability of the Arm, Shoulder and Hand questionnaire (DASH) and the Michigan Hand Questionnaire (MHQ) at minimum 36 months post-injection.

Results: The study included 45 patients with 53 hands with a mean age of 65.7 years. The treatment was successful in 62% of patients with the greatest improvement in the metacarpal-phalangeal joint of the little finger. Diabetes, epilepsy, gender, alcohol intake and positive family history had no statistically significant predictive value on successful outcomes. Patient satisfaction at 41 months was high with mean MHQ score of 97.3.

Conclusions: Collagenase is effective in the treatment of Dupuytren contracture, with disease involving the little finger showing the greatest benefit. Risk factors for development of Dupuytren disease had no effect on successful outcome and long-term satisfaction rates are high.

Level of Evidence: Level III (Therapeutic)

Keywords:

REFERENCES

1. Hurst LC, Badalamente MA, Hentz VRet al.. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968-79. https://doi.org/10.1056/nejmoa0810866. Crossref, Medline, Google Scholar
2. Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: A new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027–38 e2021. https://doi.org/10.1016/j.jhsa.2010.08.007. Crossref, Medline, Google Scholar
3. Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren’s disease: 8-year follow-up. J Hand Surg Am. 2010;35(4):534–9 e531. https://doi.org/10.1016/j.jhsa.2010.01.003. Crossref, Medline, Google Scholar
4. Badalamente MA, Hurst LC, Benhaim P, Cohen BM. Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in Dupuytren contracture: combined analysis of 4 phase 3 clinical trials. J Hand Surg Am. 2015;40(5):975–83. https://doi.org/10.1016/j.jhsa.2015.02.018. Crossref, Medline, Google Scholar
5. Poelstra R, van Kooij YE, van der Oest MJWet al.. Patient’s satisfaction beyond hand function in Dupuytren’s disease: Analysis of 1106 patients. J Hand Surg Eur Vol. 2020;45(3):280-5. https://doi.org/10.1177/1753193419890284. Crossref, Medline, Google Scholar
6. Godtfredsen NS, Lucht H, Prescott E, Sorensen TI, Gronbaek M. A prospective study linked both alcohol and tobacco to Dupuytren’s disease. J Clin Epidemiol. 2004;57(8):858–63. https://doi.org/10.1016/j.jclinepi.2003.11.015. Crossref, Medline, Google Scholar
7. Descatha A, Bodin J, Ha Cet al.. Heavy manual work, exposure to vibration and Dupuytren’s disease? Results of a surveillance program for musculoskeletal disorders. Occup Environ Med. 2012;69(4):296–9. https://doi.org/10.1136/oemed-2011-100319. Crossref, Medline, Google Scholar
8. Picardo NE, Khan WS. Advances in the understanding of the aetiology of Dupuytren’s disease. Surgeon. 2012;10(3):151–8. https://doi.org/10.1016/j.surge.2012.01.004. Crossref, Medline, Google Scholar
9. Nunn AC, Schreuder FB. Dupuytren’s contracture: Emerging insight into a Viking disease. Hand Surg. 2014;19(3):481–90. https://doi.org/10.1142/s0218810414300058. Link, Google Scholar
10. Shauver MJ, Chung KC. The Michigan hand outcomes questionnaire after 15 years of field trial. Plast Reconstr Surg. 2013;131(5):779e–87e. https://doi.org/10.1097/prs.0b013e3182865d83. Crossref, Medline, Google Scholar
11. Noble J, Arafa M, Royle SG, McGeorge G, Crank S. The association between alcohol, hepatic pathology and Dupuytren’s disease. J Hand Surg Br. 1992;17(1):71–4. https://doi.org/10.1016/0266-7681(92)90015-t. Crossref, Medline, Google Scholar
12. Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren’s disease. J Bone Joint Surg Br. 1984;66(3):322–5. Crossref, Medline, Google Scholar
13. Arafa M, Noble J, Royle SG, Trail IA, Allen J. Dupuytren’s and epilepsy revisited. J Hand Surg Br. 1992;17(2):221–4. https://doi.org/10.1016/0266-7681(92)90095-j. Crossref, Medline, Google Scholar
14. Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T. Epidemiology of Dupuytren’s disease: Clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol. 2000;53(3):291–6. https://doi.org/10.1016/s0895-4356(99)00145-6. Crossref, Medline, Google Scholar
15. Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren’s contracture. J Bone Joint Surg Br. 1997;79(2):206–10. Crossref, Medline, Google Scholar
16. Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: Short-term results from 2 open-label studies. J Hand Surg Am. 2013;38(1):2–11. https://doi.org/10.1016/j.jhsa.2012.10.008. Crossref, Medline, Google Scholar
17. Coleman S, Gilpin D, Kaplan FTet al.. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39(1):57–64. https://doi.org/10.1016/j.jhsa.2013.10.002. Crossref, Medline, Google Scholar
18. Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol. 2015;40(2):141–9. https://doi.org/10.1177/1753193414528843. Crossref, Medline, Google Scholar
19. Zhou C, Hovius SE, Slijper HPet al.. Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren’s Contracture: Outcomes from a Multicenter Propensity Score Matched Study. Plast Reconstr Surg. 2015;136(1):87–97. https://doi.org/10.1097/prs.0000000000001320. Crossref, Medline, Google Scholar
20. Considine S, Heaney R, Hirpara KM. Early results of the use of collagenase in the treatment of Dupuytren’s contracture. Ir J Med Sci. 2015;184(2):323–7. https://doi.org/10.1007/s11845-014-1111-6. Crossref, Medline, Google Scholar
21. Gaston RG, Larsen SE, Pess GMet al.. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 2015;40(10):1963– 71. https://doi.org/10.1016/j.jhsa.2015.06.099. Crossref, Medline, Google Scholar
22. Atroshi I, Nordenskjold J, Lauritzson A, Ahlgren E, Waldau J, Walden M. Collagenase treatment of Dupuytren’s contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome. Acta Orthop. 2015;86(3):310–5. https://doi.org/10.3109/17453674.2015.1019782. Crossref, Medline, Google Scholar
23. Smeraglia F, Del Buono A, Maffulli N. Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review. Br Med Bull. 2016;118(1):149–58. https://doi.org/10.1093/bmb/ldw020. Crossref, Medline, Google Scholar
24. Leclere FM, Kohl S, Varonier C, Unglaub F, Vogelin E. Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1–3: Collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients. Arch Orthop Trauma Surg. 2018;138(11):1623–31. https://doi.org/10.1007/s00402-018-3034-6. Crossref, Medline, Google Scholar
25. Degreef I. Collagenase Treatment in Dupuytren Contractures: A Review of the Current State Versus Future Needs. Rheumatol Ther. 2016;3(1):43–51. https://doi.org/10.1007/s40744-016-0027-1. Crossref, Medline, Google Scholar
26. Sanjuan-Cervero R. Current role of the collagenase Clostridium histolyticum in Dupuytren’s disease treatment. Ir J Med Sci. 2020;189(2):529–534. https://doi.org/10.1007/s11845-019-02127-z. Crossref, Medline, Google Scholar
27. Sefton AK, Smith BJ, Stewart DA. Cost comparison of collagenase clostridium histolyticum and fasciectomy for treatment of Dupuytren’s contracture in the Australian health system. J Hand Surg Asian Pac Vol. 2018;23(3):336–41. https://doi.org/10.1142/s2424835518500327. Link, Google Scholar
28. Cocci A, Russo GI, Salamanca JIM, Ralph D, Palmieri A, Mondaini N. The end of an era: withdrawal of Xiapex (clostridium histolyticum collagenase) from the European market. Eur Urol. 2020;77(5):660–1. https://doi.org/10.1016/j.eururo.2019.11.019. Crossref, Medline, Google Scholar